Advanced search

Online first
Review paper
Published online: 2024-12-05

open access

View PDF Download PDF file
Page views 40
Article views/downloads 49
Get Citation

Connect on Social Media

Connect on Social Media

The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy

Mariusz Nowak1, Wojciech Nowak2, Bogdan Marek1, Beata Kos-Kudła3, Lucyna Siemińska1, Magdalena Londzin-Olesik3, Dariusz Kajdaniuk1

Abstract

Since the European Thyroid Association guidelines for the management of thyroid orbitopathy (TO) were published in 2016, a number of randomised clinical trials (RCTs) investigating the use of biologic drugs for the treatment of moderate to severe and active TO have been published. Therefore, new recommendations for its treatment were developed and published in 2021. Treatment of active TO includes 2 types of immunosuppressive agents: non-specific and specific. Specific immunosuppressive agents used to treat TO include adalimumab (ADA), infliximab (IFX), etanercept (ETA), rituximab (RTX), tocilizumab (TCZ), teprotumumab (TEP), and batoclimab (BAT). In the manuscript, we present a review of the literature on RCTs, retrospective studies, and case reports on their use in the treatment of TO.

The authors emphasise the beneficial effects of TEP, indicating, however, the lack of data on its long-term efficacy and safety and the lack of head-to-head comparison with i.v. glucocorticosteroids and its huge limitation is also the high price of the drug. TCZ is a therapeutic option for glucocorticosteroid-resistant TO and should be considered for second-line treatment (due to the cost of treatment, among other reasons) or first-line treatment in patients with contraindications to i.v. glucocorticosteroids. Given its side-effect profile, especially some risk of optic nerve neuropathy (DON), RTX is considered by the authors as a second- or even third-line treatment option. The current 2021 European Group on Graves’ Orbitopathy (EUGOGO) recommendations include RTX, TCZ, and TEP among the second-line drugs for the treatment of moderate to severe and active TO. BAT is under clinical trials. Given the numerous advantages of biologic drugs over glucocorticosteroids, further RCTs are indicated to confirm their possible place also as first-line treatment in TO.

Keywords: Graves’/Basedow’s diseasetreatmentmonoclonal antibodiessmall molecules

Article available in PDF format

View PDF Download PDF file

References

  1. Bartalena L, Baldeschi L, Boboridis K, et al. European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016; 5(1): 9–26.
    CrossRefPubMed
  2. Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Tocilizumab in Graves Orbitopathy Study Group. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol. 2018; 195: 181–190.
    CrossRefPubMed
  3. Kahaly GJ, Riedl M, König J, et al. European Group on Graves' Orbitopathy (EUGOGO). Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018; 6(4): 287–298.
    CrossRefPubMed
  4. Jain AP, Gellada N, Ugradar S, et al. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol. 2022; 106(2): 165–171.
    CrossRefPubMed
  5. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. N Engl J Med. 2020; 382(4): 341–352.
    CrossRefPubMed
  6. Bartalena L, Kahaly GJ, Baldeschi L, et al. EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021; 185(4): G43–G67.
    CrossRefPubMed
  7. Nowak M, Marek B, Kos-Kudła B, et al. Optimization of the treatment of moderate to severe and active thyroid orbitopathy considering the recommendations of the European Group on Graves' Orbitopathy (EUGOGO) [Optymalizacja leczenia umiarkowanej do ciężkiej i aktywnej orbitopatii tarczycowej z uwzględnieniem zaleceń European Group on Graves' Orbitopathy (EUGOGO)]. Endokrynol Pol. 2022; 73(4): 756–777.
    CrossRefPubMed
  8. Łacheta D, Miśkiewicz P, Głuszko A, et al. Immunological Aspects of Graves' Ophthalmopathy. Biomed Res Int. 2019; 2019: 7453260.
    CrossRefPubMed
  9. Place RF, Krieger CC, Neumann S, et al. Inhibiting thyrotropin/insulin-like growth factor 1 receptor crosstalk to treat Graves' ophthalmopathy: studies in orbital fibroblasts in vitro. Br J Pharmacol. 2017; 174(4): 328–340.
    CrossRefPubMed
  10. Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol. 2008; 181(6): 4397–4405.
    CrossRefPubMed
  11. Chitnis MM, Yuen JSP, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008; 14(20): 6364–6370.
    CrossRefPubMed
  12. Smith TJ, Hegedüs L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012; 26(3): 291–302.
    CrossRefPubMed
  13. Ugradar S, Shi Lu, Wang Y, et al. Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression. Eye (Lond). 2021; 35(9): 2607–2612.
    CrossRefPubMed
  14. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev. 2010; 62(2): 199–236.
    CrossRefPubMed
  15. Krieger CC, Neumann S, Place RF, et al. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins. J Clin Endocrinol Metab. 2015; 100(3): 1071–1077.
    CrossRefPubMed
  16. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004; 89(10): 5076–5080.
    CrossRefPubMed
  17. Renier G, Clément I, Desfaits AC, et al. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology. 1996; 137(11): 4611–4618.
    CrossRefPubMed
  18. Kooijman R, Coppens A, Hooghe-Peters E. IGF-I stimulates IL-8 production in the promyelocytic cell line HL-60 through activation of extracellular signal-regulated protein kinase. Cell Signal. 2003; 15(12): 1091–1098.
    CrossRefPubMed
  19. Ren Z, Zhang H, Yu H, et al. Roles of four targets in the pathogenesis of graves' orbitopathy. Heliyon. 2023; 9(9): e19250.
    CrossRefPubMed
  20. Iyer S, Bahn R. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab. 2012; 26(3): 281–289.
    CrossRefPubMed
  21. Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf). 2000; 52(3): 267–271.
    CrossRefPubMed
  22. Świerkot M, Kulawik G, Sarnat-Kucharczyk M, et al. Long-term remission of steroid-resistant Graves' orbitopathy after administration of anti-thymocyte globulin. Endokrynol Pol. 2020; 71(2): 198–199.
    CrossRefPubMed
  23. Miśkiewicz P, Kryczka A, Ambroziak U, et al. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe? Endokrynol Pol. 2014; 65(5): 402–413.
    CrossRefPubMed
  24. Zang S, Ponto KA, Kahaly GJ. Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011; 96(2): 320–332.
    CrossRefPubMed
  25. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med. 1989; 321(20): 1353–1359.
    CrossRefPubMed
  26. Chalvatzis NT, Tzamalis AK, Kalantzis GK, et al. Safety and efficacy of combined immunosuppression and orbital radiotherapy in thyroid-related restrictive myopathy: two-center experience. Eur J Ophthalmol. 2014; 24(6): 953–959.
    CrossRefPubMed
  27. Allam MM, El-Zawawy HT, Kader Okda AA, et al. Azathioprine as an adjuvant therapy in severe Graves' disease: a randomized controlled open-label clinical trial. Front Endocrinol (Lausanne). 2023; 14: 1168936.
    CrossRefPubMed
  28. Shen L, Ye L, Zhu W, et al. Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy. Eur Thyroid J. 2022; 11(5).
    CrossRefPubMed
  29. Rivera-Grana E, Lin P, Suhler EB, et al. Methotrexate as a Corticosteroid-Sparing Agent for Thyroid Eye Disease. J Clin Exp Ophthalmol. 2015; 6(2).
    CrossRefPubMed
  30. Strianese D, Iuliano A, Ferrara M, et al. Methotrexate for the treatment of thyroid eye disease. J Ophthalmol. 2014; 2014: 128903.
    CrossRefPubMed
  31. Feng W, Hu Y, Zhang C, et al. Efficacy and safety of mycophenolate mofetil in the treatment of moderate to severe Graves' orbitopathy: a meta-analysis. Bioengineered. 2022; 13(6): 14719–14729.
    CrossRefPubMed
  32. Kahaly GJ, Dolman PJ, Wolf J, et al. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease. J Clin Endocrinol Metab. 2023; 108(12): 3122–3134.
    CrossRefPubMed
  33. Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye (Lond). 2005; 19(12): 1286–1289.
    CrossRefPubMed
  34. Komorowski J, Jankiewicz-Wika J, Siejka A, et al. Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy. Klin Oczna. 2007; 109(10-12): 457–460.
    PubMed
  35. van Steensel L, van Hagen PM, Paridaens D, et al. Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy. Br J Ophthalmol. 2011; 95(5): 735–738.
    CrossRefPubMed
  36. Ayabe R, Rootman DB, Hwang CJ, et al. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014; 30(5): 415–419.
    CrossRefPubMed
  37. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008; 117(2): 244–279.
    CrossRefPubMed
  38. Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit. 2005; 24(2): 117–119.
    CrossRefPubMed
  39. Boskovic O, Medenica S, Radojevic N, et al. Etanercept in the treatment of Graves' ophthalmopathy with primary hypothyroidism and rheumatoid arthritis. Cent Eur J Immunol. 2019; 44(4): 463–465.
    CrossRefPubMed
  40. Stan MN, Garrity JA, Carranza Leon BG, et al. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab. 2015; 100(2): 432–441.
    CrossRefPubMed
  41. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007; 156(1): 33–40.
    CrossRefPubMed
  42. Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015; 100(2): 422–431.
    CrossRefPubMed
  43. Karasek D, Cibickova L, Karhanova M, et al. Clinical and immunological changes in patients with active moderate-to-severe Graves' orbitopathy treated with very low-dose rituximab. Endokrynol Pol. 2017; 68(5): 498–504.
    CrossRefPubMed
  44. ACTEMRA® (tocilizumab) [package insert] Injection, for Intravenous or Subcutaneous Use. Full Prescribing Information. South San Francisco, CA: Genentech, Inc.; 2019. .
  45. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008; 371(9617): 987–997.
    CrossRefPubMed
  46. Bijlsma JWJ, Welsing PMJ, Woodworth TG, et al. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet. 2016; 388(10042): 343–355.
    CrossRefPubMed
  47. Russell DJ, Wagner LH, Seiff SR. Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy. Am J Ophthalmol Case Rep. 2017; 7: 146–148.
    CrossRefPubMed
  48. Pérez-Moreiras JV, Varela-Agra M, Prada-Sánchez MC, et al. Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience. J Clin Med. 2021; 10(4).
    CrossRefPubMed
  49. Sánchez-Bilbao L, Martínez-López D, Revenga M, et al. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients. J Clin Med. 2020; 9(9).
    CrossRefPubMed
  50. Ceballos-Macías José J, Rivera-Moscoso R, Flores-Real Jorge A, et al. Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population. Ann Endocrinol (Paris). 2020; 81(2-3): 78–82.
    CrossRefPubMed
  51. Dorado Cortez O, Grivet D, Perrillat N, et al. Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab: a single-centre prospective study. Orbit. 2023; 42(4): 411–417.
    CrossRefPubMed
  52. Moi L, Hamedani M, Ribi C. Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab. Clin Endocrinol (Oxf). 2022; 97(3): 363–370.
    CrossRefPubMed
  53. Rymuza J, Kuś A, Białas-Niedziela D, et al. Long-term remission of corticosteroid-resistant Graves' orbitopathy after therapy with tocilizumab. Endokrynol Pol. 2024; 75(1): 117–118.
    CrossRefPubMed
  54. Albrashdi S, Alsharqi H, Habroosh F, et al. Tocilizumab use in pediatric thyroid eye disease: First documented case. Am J Ophthalmol Case Rep. 2022; 25: 101387.
    CrossRefPubMed
  55. Smith TJ, Janssen JA. Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy. Front Endocrinol (Lausanne). 2016; 7: 167.
    CrossRefPubMed
  56. Smith TJ, Janssen JA. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. Endocr Rev. 2019; 40(1): 236–267.
    CrossRefPubMed
  57. Mohyi M, Smith TJ. IGF1 receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol. 2018; 61(1): T29–T43.
    CrossRefPubMed
  58. Horizon Therapeutics USA Inc. TEPEZZA — teprotumumab injection, powder, lyophilized, for solution: US prescribing information. 2022. https://dailymed.nlm.nih.gov/dailymed (28.10.2022).
  59. Xin Y, Xu F, Gao Y, et al. Pharmacokinetics and Exposure-Response Relationship of Teprotumumab, an Insulin-Like Growth Factor-1 Receptor-Blocking Antibody, in Thyroid Eye Disease. Clin Pharmacokinet. 2021; 60(8): 1029–1040.
    CrossRefPubMed
  60. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. N Engl J Med. 2017; 376(18): 1748–1761.
    CrossRefPubMed
  61. Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Ophthalmology. 2022; 129(4): 438–449.
    CrossRefPubMed
  62. Ugradar S, Wang Y, Mester T, et al. Teprotumumab for thyroid eye disease: early response is not required for benefit. Eye (Lond). 2022; 36(7): 1403–1408.
    CrossRefPubMed
  63. Diniz SB, Cohen LM, Roelofs KA, et al. Early Experience With the Clinical Use of Teprotumumab in a Heterogenous Thyroid Eye Disease Population. Ophthalmic Plast Reconstr Surg. 2021; 37(6): 583–591.
    CrossRefPubMed
  64. Sears CM, Azad AD, Dosiou C, et al. Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy. Ophthalmic Plast Reconstr Surg. 2021; 37(3S): S157–S160.
    CrossRefPubMed
  65. Slentz DH, Smith TJ, Kim DS, et al. Teprotumumab for Optic Neuropathy in Thyroid Eye Disease. JAMA Ophthalmol. 2021; 139(2): 244–247.
    CrossRefPubMed
  66. Chiou CA, Reshef ER, Freitag SK. Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases. Am J Ophthalmol Case Rep. 2021; 22: 101075.
    CrossRefPubMed
  67. Lopez MJ, Herring JL, Thomas C, et al. Visual Recovery of Dysthyroid Optic Neuropathy With Teprotumumab. J Neuroophthalmol. 2022; 42(2): e491–e493.
    CrossRefPubMed
  68. Hwang CJ, Nichols EE, Chon BH, et al. Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab. Eur J Ophthalmol. 2022; 32(3): NP46–NP49.
    CrossRefPubMed
  69. Jurek-Matusiak O, Brożek-Mądry E, Jastrzębska H, et al. Orbital decompression for thyroid eye disease: surgical treatment outcomes in endocrinological assessment. Endokrynol Pol. 2021; 72(6): 609–617.
    CrossRefPubMed
  70. Kahaly GJ, Douglas RS, Holt RJ, et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021; 9(6): 360–372.
    CrossRefPubMed
  71. Smith T, Bhattacharya R, Hsu K, et al. PSAT265 Blood Glucose in Thyroid Eye Disease (TED) in Patients treated with Teprotumumab: Clinical Trials Data. J Endocrin Soc. 2022; 6(Suppl_1): A809–A809.
    CrossRef
  72. Belinsky I, Creighton FX, Mahoney N, et al. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring. Ophthalmic Plast Reconstr Surg. 2022; 38(1): 73–78.
    CrossRefPubMed
  73. Chow A, Silkiss RZ. Teprotumumab-associated chronic hearing loss screening and proposed treatments. BMJ Case Rep. 2022; 15(4).
    CrossRefPubMed
  74. Sears CM, Azad AD, Amarikwa L, et al. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease. Am J Ophthalmol. 2022; 240: 1–13.
    CrossRefPubMed
  75. Burch HB, Perros P, Bednarczuk T, et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J. 2022; 11(6).
    CrossRefPubMed
  76. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol. 1996; 12: 181–220.
    CrossRefPubMed
  77. Lozano NA, Lozano A, Marini V, et al. Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns. Am J Reprod Immunol. 2018; 80(3): e12972.
    CrossRefPubMed
  78. Pyzik M, Kozicky LK, Gandhi AK, et al. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023; 23(7): 415–432.
    CrossRefPubMed
  79. Yan C, Duan RS, Yang H, et al. Therapeutic Effects of Batoclimab in Chinese Patients with Generalized Myasthenia Gravis: A Double-Blinded, Randomized, Placebo-Controlled Phase II Study. Neurol Ther. 2022; 11(2): 815–834.
    CrossRefPubMed
  80. Bhandari V, Bril V. FcRN receptor antagonists in the management of myasthenia gravis. Front Neurol. 2023; 14: 1229112.
    CrossRefPubMed
  81. Sesarman A, Sitaru AG, Olaru F, et al. Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita. J Mol Med (Berl). 2008; 86(8): 951–959.
    CrossRefPubMed
  82. Janes J, Kahaly G, Liang Su, et al. ODP509 Proof-of-concept, Multicenter, Open-Label Phase 2a Study of Batoclimab in Active and Moderate-to-Severe Thyroid Eye Disease. J Endocrin Soc. 2022; 6(Suppl_1): A778–A779.
    CrossRef
  83. Kahaly GJ, Dolman PJ, Wolf J, et al. Proof-of-concept and Randomized, Placebo-controlled Trials of an FcRn Inhibitor, Batoclimab, for Thyroid Eye Disease. J Clin Endocrinol Metab. 2023; 108(12): 3122–3134.
    CrossRefPubMed
  84. Collins J, Jones L, Snyder M, et al. RVT-1401, A Novel Anti-FcRn Monoclonal Antibody, Is Well Tolerated in Healthy Subjects and Reduces Plasma IgG Following Subcutaneous or Intravenous Administration (P5.2-079). Neurology. 2019; 92(15_suppl).
    CrossRef
  85. Davies TF, Andersen S, Latif R, et al. Graves' disease. Nat Rev Dis Primers. 2020; 6(1): 52.
    CrossRefPubMed
  86. Neumann S, Kleinau G, Costanzi S, et al. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology. 2008; 149(12): 5945–5950.
    CrossRefPubMed
  87. Bahn RS. Autoimmunity and Graves' disease. Clin Pharmacol Ther. 2012; 91(4): 577–579.
    CrossRefPubMed
  88. Gershengorn MC, Neumann S. Update in TSH receptor agonists and antagonists. J Clin Endocrinol Metab. 2012; 97(12): 4287–4292.
    CrossRefPubMed
  89. Turcu AF, Kumar S, Neumann S, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013; 98(5): 2153–2159.
    CrossRefPubMed
  90. Evans M, Sanders J, Tagami T, et al. Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin Endocrinol (Oxf). 2010; 73(3): 404–412.
    CrossRefPubMed
  91. Furmaniak J, Sanders J, Sanders P, et al. TSH receptor specific monoclonal autoantibody K1-70 targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy-Results from a phase I clinical trial. Clin Endocrinol (Oxf). 2022; 96(6): 878–887.
    CrossRefPubMed
  92. Puzanov I, Lindsay CR, Goff L, et al. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res. 2015; 21(4): 701–711.
    CrossRefPubMed
  93. Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem. 2009; 1(6): 1153–1171.
    CrossRefPubMed
  94. Gulbins A, Horstmann M, Daser A, et al. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Front Endocrinol (Lausanne). 2023; 14: 1211473.
    CrossRefPubMed
  95. Wang Y, Patel A, Douglas RS. Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm. Ther Clin Risk Manag. 2019; 15: 1305–1318.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note